Dr. Hurvitz on the Key Objectives of DESTINY-Breast03 in HER2+ Breast Cancer
December 22, 2021, 12:42 am
Sara A. Hurvitz, MD, discusses the rationale for the phase 3 DESTINY-Breast03 trial examining in HER2-positive breast cancer.
Curated, Global, Hometown News for the City and Citizens of Santa Monica California
Dr. Hurvitz on the Key Objectives of DESTINY-Breast03 in HER2+ Breast Cancer
COPYRIGHT © Indian Hill Media Inc. Another Smiling Dog Web Development. Hosted by InlandEmpire.IO ALL RIGHTS RESERVED.
COPYRIGHT © Indian Hill Media Inc. Another Smiling Dow Web Development. Hosted by InlandEmpire.IO ALL RIGHTS RESERVED.
